Denali Therapeutics (DNLI) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is DNLI's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Fisher Asset Management LLC boosted its position in Denali Therapeutics Inc. (NASDAQ: DNLI) by 1.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institu…

Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript…

I initiate Denali Therapeutics at Buy, as the Avlayah launch has validated the TransportVehicle platform and turned DNLI into a commercial-stage story. Q3 Avlayah sales of $17.8M crushed the $10-12M guide, and Q4 guidanc…

Denali Therapeutics NASDAQ: DNLI is targeting all eligible U.S. patients for its Hunter disease treatment AVLAYAH, while preparing data updates across a pipeline that includes treatments for Sanfilippo syndrome, Pompe di…

Denali Therapeutics gains 7.8% as Avlayah sales surge nearly fivefold, reimbursement coverage expands and multiple pipeline catalysts approach.…

Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript…

Denali Therapeutics NASDAQ: DNLI reported third-quarter 2026 net product revenue of $17.8 million from AVLAYAH, its treatment for Hunter syndrome, as expanding payer coverage and transitions of clinical-trial participant…

Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $0.74 per share a year ago.…

AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarter Continued growth expectations drive Q4 2026 net product revenue guidance of $30.0 million to $32.0 …

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that AVLAYAH® (tividenofusp alfa-eknm) has been recognized as the “Best Biotechnology Product” of 202…

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the third quarter ended September 3…

Engineers Gate Manager LP lifted its position in Denali Therapeutics Inc. (NASDAQ: DNLI) by 256.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission…

WINTON GROUP Ltd decreased its position in Denali Therapeutics Inc. (NASDAQ: DNLI) by 80.2% during a recent quarter, according to its most recent disclosure with the SEC. The fund owned 14,100 shares of the company's sto…

Altimmune (NASDAQ: ALT - Get Free Report) and Denali Therapeutics (NASDAQ: DNLI - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strengt…

Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

BlackRock Inc. bought a new stake in Denali Therapeutics Inc. (NASDAQ: DNLI) in a recent quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 14,026,…

Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.…

AVLAYAH's approval has helped validate Denali Therapeutics' TransportVehicle platform. They're now moving into their commercial stage as a business. Early payer coverage and Q3 guidance support a credible launch ramp. Ho…

Denali Therapeutics (NASDAQ: DNLI - Get Free Report) and Humacyte (NASDAQ: HUMA - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength …
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

